You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 6,376,515


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,376,515
Title: Benzamides and related inhibitors of factor Xa
Abstract:Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Inventor(s): Zhu; Bing-Yan (Belmont, CA), Zhang; Penglie (Foster City, CA), Wang; Lingyan (Chatham, NJ), Huang; Wenrong (Cupertino, CA), Goldman; Erick A. (San Francisco, CA), Li; Wenhao (South San Francisco, CA), Zuckett; Jingmei (Glendale, AZ), Song; Yonghong (Foster City, CA), Scarborough; Robert M. (Half Moon Bay, CA)
Assignee: COR Therapeutics, Inc. (South San Francisco, CA)
Application Number:09/794,225
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Device;
Patent landscape, scope, and claims:

United States Patent 6,376,515: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 6,376,515, granted to Bing-Yan Zhu and Penglie Zhang, is a significant patent in the pharmaceutical industry, particularly in the field of anticoagulant drugs. This patent is associated with betrixaban, a factor Xa inhibitor marketed under the brand name BEVYXXA®. Here, we delve into the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

Grant and Ownership

The patent was granted on April 23, 2002, and is owned by Millennium Pharmaceuticals, Inc., which is the assignee of the entire interest in the patent[1].

Scope of the Patent

Claims

The '515 Patent includes 72 claims, which are comprehensive and cover various aspects of betrixaban and its uses. Key claims include:

  • Compound Claims: Claims 1, 14, 19, 20, and 21 specifically claim betrixaban, pharmaceutical compositions comprising betrixaban, and approved methods of using betrixaban[1].
  • Method of Use Claims: These claims cover the methods of using betrixaban for therapeutic purposes, such as preventing and treating thromboembolic disorders.
  • Manufacturing Claims: The patent also includes claims related to the methods of manufacturing betrixaban and its pharmaceutical compositions.

Formula and Structure

The patent describes a compound of formula VI, which includes specific structural elements such as C1-C6 alkyl groups that may be optionally substituted with hydroxyl, carboxylic acid, or carboxylic acid ester groups. The formula also specifies the positions and types of other functional groups[1].

Patent Term Extension

Regulatory Review Period

The patent is eligible for a term extension under 35 U.S.C. § 156 due to the lengthy regulatory review period for the approved product, BEVYXXA®. The regulatory review period was calculated from the effective date of the Investigational New Drug (IND) application (November 30, 2005) to the approval of the New Drug Application (NDA) (June 23, 2017), totaling 4,225 days[1].

Calculation of Extension

The term extension was calculated by subtracting the days before the patent issuance and any days where the applicant did not act with due diligence from the total regulatory review period. This resulted in an extension of 2,234 days[1].

Patent Landscape

Related Patents

Several other patents are related to the preparation and recovery of betrixaban, such as U.S. Patent 8,394,964 B2. This patent describes methods for preparing and recovering betrixaban free base or its salts, indicating a broader landscape of intellectual property surrounding this compound[2].

Patent Scope and Quality

The scope of the '515 Patent is significant, with 72 claims that cover a wide range of aspects related to betrixaban. This aligns with discussions on patent scope and quality, where broader patents can sometimes be seen as overly broad or lacking in clarity. However, the '515 Patent's claims are specific and well-defined, which is crucial for maintaining patent quality and avoiding unnecessary litigation[3].

Impact on Innovation

Licensing and Litigation

The breadth and clarity of the '515 Patent's claims can influence innovation in the pharmaceutical industry. Well-defined claims can reduce licensing and litigation costs, thereby encouraging further innovation. The patent's extension under 35 U.S.C. § 156 also reflects the significant investment in time and resources required for regulatory approval, which can be a barrier to entry for other innovators[3].

Industry Expert Insights

Industry experts often highlight the importance of clear and specific patent claims. For example, "Narrower claims at publication are associated with a higher probability of grant and a shorter examination process than broader claims," indicating that the '515 Patent's detailed claims may have facilitated its approval and subsequent extensions[3].

Regulatory Compliance

FDA Approval

The approval of BEVYXXA® by the FDA is a critical milestone that validates the patent's claims. The regulatory review process, which spanned over 4,200 days, underscores the rigorous standards that pharmaceutical products must meet before they are approved for market[1].

Economic and Market Impact

Market Domination

The exclusive rights granted by the '515 Patent allow Millennium Pharmaceuticals to dominate the market for betrixaban-based anticoagulant drugs. This exclusivity can impact market dynamics, pricing, and access to the drug, highlighting the significant economic implications of pharmaceutical patents[1].

Conclusion

United States Patent 6,376,515 is a pivotal patent in the pharmaceutical industry, particularly in the area of anticoagulant therapy. Its comprehensive claims, detailed structural descriptions, and regulatory extensions underscore its importance. The patent's impact on innovation, licensing, and market dynamics is substantial, reflecting the complex interplay between intellectual property, regulatory compliance, and market competition.

Key Takeaways

  • Comprehensive Claims: The patent includes 72 claims covering betrixaban, its pharmaceutical compositions, and methods of use and manufacture.
  • Regulatory Extensions: The patent was extended under 35 U.S.C. § 156 due to a lengthy regulatory review period.
  • Impact on Innovation: Clear and specific claims can reduce licensing and litigation costs, encouraging innovation.
  • Market Exclusivity: The patent grants exclusive rights, allowing the owner to dominate the market for betrixaban-based drugs.
  • Regulatory Compliance: The patent's approval and extensions are tied to rigorous FDA regulatory standards.

FAQs

What is the main compound claimed in U.S. Patent 6,376,515?

The main compound claimed is betrixaban, a factor Xa inhibitor.

How many claims are included in the '515 Patent?

The patent includes 72 claims.

Why was the '515 Patent eligible for a term extension?

The patent was eligible due to the lengthy regulatory review period for the approved product, BEVYXXA®.

What is the significance of the regulatory review period in patent term extension?

The regulatory review period, totaling 4,225 days, justified the extension of the patent term by 2,234 days.

How does the scope of the '515 Patent impact innovation in the pharmaceutical industry?

The clear and specific claims reduce licensing and litigation costs, thereby encouraging further innovation in the industry.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,376,515

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.